Shilpa Medicare hits record high on USFDA nod for cancer drug

Shilpa Medicare rallied 3.31% to Rs 756.85 after the company announced that it has received the U.S. Food and Drug Administration (USFDA) approval for its second new drug application (NDA), Bortezomib injection.